- Supported exchanges /
- KQ /
- 078160.KQ
MEDIPOST Co. Ltd (078160 KQ) stock market data APIs
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease. Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand name. MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
MEDIPOST Co. Ltd Financial Data Overview
| 8390 | |
| 8230 | |
| - | |
| 8410 | |
| 7930 | |
| 5450-8960 | |
| 281 997 M | |
| 15 380 K | |
| 62 413 M | |
| -534.121 | |
| 0.7781 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
MEDIPOST Co. Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 62 413 M
- EBITDA -10 798 811 136
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get MEDIPOST Co. Ltd Earnings via APIs
- Latest Release 2024-11-12
- EPS/Forecast NaN
Get MEDIPOST Co. Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
